KROS vs LLY

Keros Therapeutics still possesses significant long-term 10x potential due to its deep pipeline targeting large unmet medical needs via the validated TGF-beta pathway. The Takeda licensing deal for KER-012, now progressing to Phase 3, validates the platform and offers future milestones. However, recent Q1 2026 earnings were abysmal, showing a near 100% year-over-year revenue decline and a swing to...

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...